Lecanemab is the first FDA approved drug to modify the course of Alzheimer disease. It was used to reduce the amount of amyloid in the brains of the patients with early Alzheimer’s and slowed the cognitive and functional decline
Lecanemab is a monoclonal antibody targeting amyloid beta protofibrils and plaques in the brain . It administered through intravenous infusion and indicated for the people with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease
Lecanemab is a major breakthrough it’s the first FDA-approved drug shown to slow Alzheimer’s progression by targeting amyloid plaques in early stages. Studies show about a 27% reduction in cognitive decline over 18 months . While side effects like brain swelling (ARIA) are possible, real-world data suggest serious reactions are rare (around 1%) when patients are carefully monitored . This gives hope but also calls for access and safety planning moving forward.
This is truly a game changer for Alzheimer’s treatment. Although the side effects can be improved with more clinical trials and formulation improvements over time, this is nonetheless a big step forward.